What missed opportunities will incumbents one day wish they had taken advantage of? Adopting a new mentality will disrupt the industry from the inside out.
Analysis on the potential effects of cost-sharing reduction payments and pass-through savings.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.
Here's what executives at Mount Sinai Health System, BCBS of Michigan, and Optum had to say about the future of healthcare at the last Oliver Wyman Health Innovation Summit.
Partners Sam Glick and Sven-Olaf Vathje write in Harvard Business Review on how countries around the world can learn from a broken American healthcare system.
What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.
CVS, Aetna, and UnitedHealthcare are just a few leading names that may forever change healthcare delivery. Should traditional health systems cling to the status quo or go with the flow?
The impact of one proposal the US Senate is considering to fund CSR payments.
Perceptions of behavioral health are evolving. Here’s why a multi-faceted approach to behavioral health brings more value to patients.